Aliskiren Synthesis via Segmentation and Parameter Control

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current processes for synthesizing aliskiren, a renin inhibitor used in treating hypertension, face challenges in achieving high total yield and diastereomeric and enantiomeric purity.

Innovation Solution

A multi-step process involving specific reaction steps and intermediates, including the conversion of compounds such as (XIII) and (XVI), with the use of metal moieties and azidation agents, to obtain aliskiren or its pharmaceutically acceptable salts with high purity.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Manufacturing precision

If conventional multistage syntheses are used to prepare aliskiren, then the compound can be obtained, but the total yield is low and the diastereomeric and enantiomeric purity is insufficient

Engineering Contradiction:
Improvediastereomeric and enantiomeric purityVSAvoidtotal yield
Core Design Contradiction:
Manufacturing precisionVSProductivity

Solution Approach 1:

The synthesis process is divided into distinct stages with specific stereochemical control at each step. The use of chiral auxiliaries and asymmetric synthesis methods allows for controlled formation of stereocenters, achieving high diastereomeric and enantiomeric purity while maintaining acceptable yield through optimized reaction conditions at each stage.

Inventive Principle:
Principle #1Segmentation

Solution Approach 2:

The invention employs specific reaction parameters including temperature control, solvent selection, and catalyst optimization to achieve high stereochemical purity. By carefully adjusting these parameters at each synthesis stage, the process achieves both high enantiomeric/diastereomeric purity and improved total yield compared to conventional methods.

Inventive Principle:
Principle #35Parameter changes

2Productivity

If conventional synthesis processes are used, then aliskiren can be produced, but the process complexity increases and overall efficiency decreases

Engineering Contradiction:
Improvesynthesis efficiencyVSAvoidprocess complexity
Core Design Contradiction:
ProductivityVSDevice complexity

Solution Approach 1:

Chiral auxiliaries and protecting groups are introduced at early stages of synthesis to pre-establish the desired stereochemistry. This preliminary action prevents the need for complex purification steps later, reducing overall process complexity while maintaining high efficiency and product purity.

Inventive Principle:
Principle #10Preliminary action

Solution Approach 2:

The invention uses specific intermediate compounds with defined stereochemistry that serve as building blocks for the final product. These intermediaries allow for modular assembly of the complex molecule, simplifying the overall process by breaking it into manageable steps with controlled stereochemistry at each stage.

Inventive Principle:
Principle #24Intermediary (Mediator)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The process enables the production of aliskiren with a purity of at least 99.5%, ensuring high diastereomeric and enantiomeric purity and total yield, making it suitable for pharmaceutical applications.

Implementation Method 1

reacting a compound of formula (XIII) or a dimer thereof with a compound of formula (XXIII) wherein Met is a metal moiety, to form a compound of formula (XVI)

Methodology Applied
Scientific EffectChemical Bonding: Chemical Bonding

Implementation Method 2

converting a compound of formula (XIX) wherein R5 is -N3 or -NR7R8

Methodology Applied
Scientific EffectChemical Bonding: Chemical Bonding

Data Source

PatentEP2189442B1Process and intermediates for the preparation of aliskiren
Publication Date: 2014.10.01 KRKA TOVARNA ZDRAVIL D D
  • EP2189442B1 patent drawingFigure 1
  • EP2189442B1 patent drawingFigure 2
  • EP2189442B1 patent drawingFigure 3

AI summary

The present invention relates to a process and intermediates for the manufacture of aliskiren or pharmaceutically acceptable salts thereof.